Implementation of the EU clinical trial regulation transforms the ethics committee systems and endangers ethical standards

Journal of Medical Ethics 47 (12):e82-e82 (2021)
  Copy   BIBTEX

Abstract

The upcoming Regulation No 536/2014 on clinical trials on medicinal products for human use, which will replace the current Clinical Trial Directive at the end of 2021, has triggered a significant reform of research ethics committee systems in Europe. Changes related to ethics review of clinical trials in the EU were considered to be essential to create a more favourable environment to conduct clinical trials in the EU. The concern is, however, that the role of the research ethics committees will weaken in at least some of the Member States because the new Regulation allows narrowing down the scope of ethics review as compared with the currently valid Clinical Trial Directive. Although the new Regulation may lead to faster approval procedures for clinical trials, which is especially relevant in the context of pandemics, high-quality ethics reviews integrating methodological aspects of a clinical trial should nevertheless be ensured. To maintain high research ethics standards as well as to foster measures to mitigate potential negative consequences of the reform, it is therefore of vital importance to start debating and sharing the reflections about the potential consequences of these transformations and trends as soon as possible.

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 97,319

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Clinical trials: two neglected ethical issues.A. Herxheimer - 1993 - Journal of Medical Ethics 19 (4):211-218.

Analytics

Added to PP
2020-12-24

Downloads
39 (#452,185)

6 months
23 (#160,587)

Historical graph of downloads
How can I increase my downloads?